Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . With its recent award of $3.35 In the US alone, AD prevalence is expected to increase from 6.5 million in 2022 to 12.7
Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
AUGUST 15, 2023
We suggest a new generation of screening assays, that better recapitulate the electrophysiology of the whole human heart, may allow better decisions across research and development. A more recent analysis has illustrated how both assay validity and reproducibility correlate across a population of simulated screening and disease models 2.
Expert insights. Personalized for you.
52 
Let's personalize your content